A Multicenter, Phase Ib/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

被引：0
|
作者：
Casasanta, Nicole
Landry, Chrystal
Shao, Theresa
Klein, Paula
Fasano, Julie
Bhardwaj, Aarti
Berger, Natalie
Moshier, Erin
Joshi, Gargi Atul
Vaccaro, Rita
Sparano, Joseph
Tiersten, Amy
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-19-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-19-11
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
    Peter Schmid
    Marie-Paule Sablin
    Jonas Bergh
    Seock-Ah Im
    Yen-Shen Lu
    Noelia Martínez
    Patrick Neven
    Keun Seok Lee
    Serafín Morales
    J. Alejandro Pérez-Fidalgo
    Douglas Adamson
    Anthony Gonçalves
    Aleix Prat
    Guy Jerusalem
    Laura Schlieker
    Rosa-Maria Espadero
    Thomas Bogenrieder
    Dennis Chin-Lun Huang
    John Crown
    Javier Cortés
    Breast Cancer Research, 23
  • [22] A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
    Schmid, Peter
    Sablin, Marie-Paule
    Bergh, Jonas
    Im, Seock-Ah
    Lu, Yen-Shen
    Martinez, Noelia
    Neven, Patrick
    Lee, Keun Seok
    Morales, Serafin
    Perez-Fidalgo, J. Alejandro
    Adamson, Douglas
    Goncalves, Anthony
    Prat, Aleix
    Jerusalem, Guy
    Schlieker, Laura
    Espadero, Rosa-Maria
    Bogenrieder, Thomas
    Huang, Dennis Chin-Lun
    Crown, John
    Cortes, Javier
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [23] Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
    Yam, Clinton
    Esteva, Francisco J.
    Patel, Miral M.
    Raghavendra, Akshara S.
    Ueno, Naoto T.
    Moulder, Stacy L.
    Hess, Kenneth R.
    Shroff, Girish S.
    Hodge, Silvia
    Koenig, Kimberly H.
    Mac Gregor, Mariana Chavez
    Griner, Robin L.
    Yeung, Sai-Ching J.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 345 - 351
  • [24] Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
    Clinton Yam
    Francisco J. Esteva
    Miral M. Patel
    Akshara S. Raghavendra
    Naoto T. Ueno
    Stacy L. Moulder
    Kenneth R. Hess
    Girish S. Shroff
    Silvia Hodge
    Kimberly H. Koenig
    Mariana Chavez Mac Gregor
    Robin L. Griner
    Sai-Ching J. Yeung
    Gabriel N. Hortobagyi
    Vicente Valero
    Investigational New Drugs, 2019, 37 : 345 - 351
  • [25] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Cardenas, Alison K.
    Cui, Na
    Wilson, Timothy R.
    Stout, Thomas J.
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387
  • [26] The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
    Lim, Elgene
    Boyle, Frances
    Okera, Meena
    Loi, Sherene
    Goksu, Sema Sezgin
    van Hal, Gertjan
    Hartman, Daisy G.
    Gable, Jonathon Colby
    Price, Gregory L.
    Hossain, Anwar
    Gainford, M. C.
    Ezquerra, Meritxell Bellet
    CANCER RESEARCH, 2020, 80 (04)
  • [27] Interim analysis of giredestrant plus inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer
    Rugo, Hope
    Gion, Maria
    Hernando, Cristina
    Jung, Kyung Hae
    Oliveira, Mafalda
    Telli, Melinda
    Vidal, Gregory
    Vatandoust, Sina
    Zhu, Jing
    Schwab, Richard
    Ngo, Huy
    Ferreira, Erika
    Collier, Ann
    Breton, Vanessa
    Gal-Yam, Einav
    CANCER RESEARCH, 2024, 84 (09)
  • [28] A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Yardley, Denise A.
    Liggett, William
    Mainwaring, Mark
    Castrellon, Aurelio
    Blakely, Laura
    Hemphill, Brian
    Anz, Bertrand, III
    Young, Robyn R.
    Shastry, Mythili
    DeBusk, Laura M.
    Hainsworth, John D.
    Burris, Howard A., III
    CLINICAL BREAST CANCER, 2020, 20 (02) : 89 - 97
  • [29] The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
    Lim, Elgene
    Boyle, Frances
    Okera, Meena
    Loi, Sherene
    Goksu, Sema S.
    van Hal, Gertjan
    Gable, Jonathon C.
    Price, Gregory L.
    Hossain, Anwar
    Gainford, Mary
    Ezquerra, Meritxell B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 124 - 125
  • [30] Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    Yeo, Belinda
    Zdenkowski, Nicholas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 3 - 14
12345